Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GYNORYLAQ
- Development stage
- Phase 1
- Lead developer
- Biogenea
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
GYNORYLAQ (specifically GYNORYLAQ-TM) is a personalized neoantigenic peptide vaccine developed by Biogenea Pharmaceuticals for the treatment of high-risk or recurrent endometrial carcinoma. The vaccine is designed using the GYNORYLAQ-EC™ quantum-classical engine, which identifies patient-specific neoantigens to elicit a targeted T-cell immune response. It is currently being evaluated in Phase I clinical trials (e.g., the GYNORYLAQ-VLINIVAL study) in combination with standard-of-care regimens. The vaccine is manufactured to GMP standards and is tailored to the unique genetic profile of each patient's tumor.
- Brand names
- GYNORYLAQ
- Other names
- GYNORYLAQ-VLINIVAL
02
Targets
MHC I (MHC class I})MHC II (Major histocompatibility complex class II receptor)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on GYNORYLAQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GYNORYLAQ.